Evaluation of Electronic Florbetapir (18F) Interpretation Training in Japanese Physicians

Avid Pharmaceuticals

Status: Withdrawn

Conditions: Alzheimer's Disease

Treatments: Drug: Florbetapir (18F)

Study type: Interventional

Funder types: Industry

Identifiers

NCT02029547

18F-AV-45-JPT01

Details and patient eligibility

About

This study is designed to validate the Japanese electronic florbetapir (18F) interpretation training program intended for post-approval implementation in Japan.

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

• Japanese Society of Nuclear Medicine (JSNM) Positron Emission Tomography (PET) Certified Nuclear Medicine Physician
• Minimal hands-on experience and no formal training in the visual interpretation of florbetapir (18F) brain PET scans
• Minimal hands-on experience and no formal training in the quantitation of florbetapir (18F) brain PET scans

Exclusion criteria

• Prior hands-on experience or formal training in the visual interpretation and/or quantitation of florbetapir (18F) PET scans

Trial design

Primary purpose: Diagnostic

Allocation: N/A

Interventional model: Single Group Assignment

Masking: Single Blind

---

0 participants in 1 patient group

Physician Readers

Experimental group

Description:

Physician readers will interpret 60 Amyvid scans using qualitative analysis followed by the use of quantitation. No subjects will be exposed to florbetapir (18F) as part of this study.

Treatment:

Drug: Florbetapir (18F)